Acupuncture treatment of hypertension with insomnia: a randomized, double-blind, placebo controlled trial research protocol

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051063

Enrollment

Unknown

Registered

2021-09-11

Start date

2021-09-12

Completion date

Unknown

Last updated

2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension with insomnia

Interventions

experimental group:In addition to taking blood pressure medications,the main acupoints are GV20, GV29, ST9, LI04.The needles will be inserted into the skin to the depth of 10-30 mm and manipulated man

control group:In addition to taking blood pressure medications,the control group will use the Streitberger Placebo-needle at the same acupoints. Needles will be retained for 30 min before removal.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 18 to 75 years, gender is not limited; 2. Meet the diagnostic criteria for hypertension (systolic blood pressure 140-180 mmHg and/or diastolic blood pressure > 90 mmHg); 3. In line with the diagnosis of insomnia according to the International Classification of Sleep Disorders (ICSD-3); 4. PSQI score > 5; 5. Have not received acupuncture treatment for at least 1 year; 6. The patient himself agreed to participate in this clinical study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with secondary hypertension; 2. Patients with serious complications such as cardiovascular, endocrine, renal and hematopoietic systems; 3. Patients with malignant tumor and mental illness; 4. Pregnant or lactating women; 5. Acupuncture acupoints or skin infections near the acupoints; 6. Insomnia caused by the external environment; 7. Patients with severe chronic obstructive pulmonary disease and bronchial asthma; 8. Patients with severe neurological dysfunction; 9. Patients with a history of alcoholism or drug dependence; 10. The researcher believes that it is not suitable to participate in this study.

Design outcomes

Primary

Measure	Time frame
PSQI questionnaire;	—

Secondary

Measure	Time frame
Sleep parameters;Blood pressure drop;Sleeping pill dosage;SDS self-rating depression scale score;SAS (Self-rating Anxiety Scale) score;	—

Countries

China

Contacts

Public ContactZhu Xun

Bao'an People's Hospital

1498010538@qq.com+86 15018513533

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026